Ann: June 2019 Quarterly Report, page-10

This from p.3:


"The company closed the June with $7 million in cash... Significantly, two of the three Phase 2 clinical trials to commence in 2019 are expected to be sustantially funded by external collaborization/strategic partners."


That pours liquidity on the Cash/Quarter burn.

Page 2 points to a long and profitable runway alleviating the suffering of patients while enriching shareholders.

I'm patient, sometimes too patient, therefore I frame the on-going Fuji talks are of a very reasonable duration when considering the enormous potential profits (see p.2) possibly stretching into the 2030s. With each party CYP, WARF, Fuji, getting essentially one BIG slice of the pie, or at the least setting the table for other agreements; partly explaining the confidential, ie. dearth of news negotiation-specific news.... It will take time.

For me the question is to BUY before the current Fuji extension, set to expire 19 September 2019 at Happy Hour. The rationale is simple: Demographics + Science = $

OV